VALIRX PLC
VAL | IL
Overview
Corporate Details
- ISIN(s):
- GB00BLH13C52
- LEI:
- 213800VQKB9SJCQDET40
- Country:
- United Kingdom
- Address:
- STONEBRIDGE HOUSE, CM22 7BD HATFIELD HEATH
- Website:
- N/A
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
ValiRx accelerates biomedical innovation, focusing on cancer and women's health treatments.Ê Our mission is to provide the scientific, financial, and commercial framework for efficient drug development. We select and incubate promising drug candidates, guiding them through development from pre-clinical studies to investor-ready assets.Ê Collaboration and integrating scientific, technical, and commercial expertise are key to our streamlined drug development process.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
Market Cap data is planned for a future update.
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
Chat, Summarize & Extract with AI!
You have of free filing views remaining.
Upgrade for unlimited access.
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-06 11:54 |
Declaration of Voting Results & Voting Rights Announcements
Holding(s) in Company
|
English | 54.3 KB | |
| 2025-06-06 08:00 |
Earnings Release
Final Results & Notice of AGM
|
English | 174.1 KB | |
| 2025-06-03 08:00 |
Regulatory News Service
New Evaluation and Material Transfer Agreement
|
English | 15.3 KB | |
| 2025-02-24 08:00 |
Regulatory News Service
Conclusion of Evaluation Project
|
English | 15.0 KB | |
| 2025-02-03 08:00 |
Business and Financial Review
Inaphaea Evaluation and Commercial Use Agreement
|
English | 17.0 KB | |
| 2025-01-30 08:00 |
Business and Financial Review
Extension of Evaluation Agreement
|
English | 15.0 KB | |
| 2025-01-29 08:00 |
Regulatory News Service
New Evaluation and Option Agreement
|
English | 15.5 KB | |
| 2025-01-15 13:47 |
Major Shareholding Notification
Holding(s) in Company
|
English | 22.1 KB | |
| 2025-01-15 12:29 |
Major Shareholding Notification
Holding(s) in Company
|
English | 54.3 KB | |
| 2025-01-14 08:00 |
Major Shareholding Notification
Holding(s) in Company
|
English | 21.9 KB | |
| 2025-01-09 12:37 |
Major Shareholding Notification
Holding(s) in Company
|
English | 52.4 KB | |
| 2025-01-09 12:14 |
Major Shareholding Notification
Holding(s) in Company
|
English | 22.0 KB | |
| 2025-01-08 08:00 |
Major Shareholding Notification
Holding(s) in Company
|
English | 21.9 KB | |
| 2025-01-02 12:45 |
Major Shareholding Notification
Holding(s) in Company
|
English | 22.0 KB | |
| 2024-12-31 14:06 |
Major Shareholding Notification
Holding(s) in Company
|
English | 21.9 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
GenSight Biologics S.A. | France | SIGHT | |
|
Gentian Diagnostics ASA | Norway | GENT | |
|
Genus PLC | United Kingdom | GNS | |
|
Grace Breeding Ltd. | Israel | GRAC | |
|
Group 107 Ltd. | Israel | G107 | |
|
Guard Therapeutics International AB | Sweden | GUARD | |
|
Gubra A/S | Denmark | GUBRA | |
|
Hadasit Bio Holding Ltd. | Israel | HDST-M | |
|
Hansa Biopharma | Sweden | HNSA | |
|
HEMOGENYX PHARMACEUTICALS PLC | United Kingdom | HEMO |